Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
J Surg Oncol. 2020 May;121(6):958-963. doi: 10.1002/jso.25848. Epub 2020 Mar 18.
The incidence of papillary thyroid microcarcinoma (microPTC) has dramatically increased in the last decades. Most of these tumors remain small and clinically "silent", only small number progress. Although thyroid surgery used to be the only therapeutic approach, recent guidelines now consider active surveillance for low-risk microPTC. For this reason, more accurate risk stratification of microPTC is needed. The optimal management of low-risk microPTC through accurate risk stratification represents a major clinical issue.
在过去几十年中,甲状腺乳头状微小癌(microPTC)的发病率显著增加。这些肿瘤大多数仍然较小且临床上“无症状”,只有少数会进展。尽管甲状腺手术曾经是唯一的治疗方法,但最近的指南现在认为对于低危 microPTC 可以进行积极监测。因此,需要对 microPTC 进行更准确的风险分层。通过准确的风险分层来管理低危 microPTC 是一个主要的临床问题。